GTC Biotherapeutics (fka GTCB)

[goatfondler]

Nothing would warrant GTCB to appreciate after a reverse stock split.

GTCB had depreciated consistently with the exception of a few spikes that quickly deflated.

There are two things that will could aid in getting this stock moving in the right direction instead of downward slope we have been riding for the past 2 or so years. One is a deal with another big pharma that pays GTCB a nice up front sum with milestones (which most likely won't happen)and the other is that ATRYN starts to sell well in Europe to bolster GTCB's revenues. The question is, "when will GTCB start to see any significant revenue from ATRYN? Maybe if things pan out, 2009? But will that be too late?

The clock is ticking on this company. Be prepared for Cox and his magnificent management team to fold like Bear Stearns soon and sell the company in the $1.50-2.00 range when the well runs dry in about 6-9 months.